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http:WHAT THIS PAPER ADDS
This study examines the outcomes following off-licence use of rFVIIa to control critical bleeding in patients
during abdominal aortic aneurysm (AAA) repair. Patients who stopped/attenuated bleeding after rFVIIa use had
a lower mortality than those with continuous bleeding. However, predictive mortality models did not show
improved survival after rFVIIa administration. Further studies are needed to more thoroughly explore the precise
role of rFVIIa in these patients with high risk of mortality as clinicians are likely to continue using rFVIIa when
conventional methods have failed and patient is at risk of exsanguination.Objective: To evaluate the outcomes following recombinant activated Factor VII (rFVIIa) use during abdominal
aortic aneurysms (AAA) repair.
Design: AAA patients were selected from the Australian and New Zealand Haemostasis Registry (ANZHR) who
received off-licence rFVIIa to control critical bleeding.
Methods: Patient characteristics and outcomes were compared between responders (bleeding stopped/
attenuated) and non-responders (bleeding continued) to rFVIIa, stratiﬁed by aneurysm status (ruptured (r-AAA)
vs. non-ruptured (nr-AAA)). Patients were also scored using POSSUM (Physiological and Operative Severity Score
for the enUmeration of Mortality and morbidity) and Hardman Index mortality predictive models.
Results: In total, 77 AAA patients were included in the analysis. Approximately 73% (n ¼ 56) of them had
ruptured aneurysms and about 50% (n¼ 35/70 with known data) responded positively to rFVIIa. Eleven incidents
of thromboembolic adverse events were reported in 9 patients (6 r-AAA and 3 nr-AAA). Responders in both
ruptured and non-ruptured groups had signiﬁcantly lower 28-day mortality than non-responders (r-AAA: 40%
(10/25) vs. 92% (24/26); P < 0.001; nr-AAA: 30% (3/10) vs. 67% (6/9); P < 0.01). Mortality predictive models did
not show any difference between overall observed and expected mortality in ANZHR patients.
Conclusion: Patients who responded to rFVIIa had a lower mortality than those who did not respond to the
treatment.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2013.01.028(AAA), including improved diagnostic techniques, introduc-
tion of endovascular aneurysm repair procedures (EVAR),
improved post-operative intensive care and an increase in
the number of specialist vascular surgeons.1,2 Despite these
advances, the mortality associated with AAA ranges from
3%e54% for elective repair of non-ruptured AAAs (nr-AAA)
to 30%e70% in ruptured AAA (r-AAA).3e8 Surgical repair
(either open procedures or EVAR) is currently the only
active treatment option available to patients with r-AAA.
However, due to uncontrolled haemorrhage and coagulop-
athy, many patients do not survive surgical intervention.9
Mechanisms postulated to be associated with coagulopathy
in r-AAA patients include consumption of platelets and
clotting factors within aneurysmal thrombi, dilution of
618 European Journal of Vascular and Endovascular Surgery Volume 45 Number 6 June/2013clotting factors and platelets through blood loss, ﬂuid
therapy and blood transfusions and the adverse effects of
acidosis and hypothermia on platelet function.10,11 Conse-
quently, there is growing interest in adjunctive therapies for
treating critical bleeding in AAA patients. Haemostatic
agents such as recombinant activated Factor VII (rFVIIa,
NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark) have
been widely used with an aim to control haemorrhage and
restore haemostasis in settings such as trauma,12,13 cardiac
surgery,14,15 liver surgery,16,17 and obstetrics.18,19 While
rFVIIa is licensed for use in the treatment of Haemophilia A
and B with inhibitors, congenital Factor VII deﬁciency and
Glanzmann’s thrombasthenia, the number of patients
receiving rFVIIa off-licence now exceeds those receiving
on-licence treatment.20 In AAA, data on the use of rFVIIa is
scarce; however, case reports and series suggest that
effective administration of rFVIIa may be associated with
improved patient outcomes.9,21,22
In this manuscript, we sought to describe the use of
rFVIIa in patients diagnosed with AAA (ruptured and non-
ruptured) and their outcomes, using data from the
Australian and New Zealand Haemostasis Registry (ANZHR).
In addition, we compared the expected versus observed
mortality in ANZHR AAA patients in different severity strata
using published mortality prediction models.
METHODS
The Australian and New Zealand Haemostasis Registry
(ANZHR)
The ANZHR is a register of non-haemophiliac patients
treated with off-licence rFVIIa for episodes of critical
bleeding in Australia and New Zealand. Details of this
registry have been previously published elsewhere.23 The
ANZHR was established in the Department of Epidemiology
and Preventive Medicine (DEPM) at Monash University and
funded through an unrestricted educational grant from
Novo Nordisk Pharmaceuticals Pty Ltd. The registry was
established in 2005 and included retrospective data
collection resulting in cases spanning a ten-year period
(2000e2009). The 96 participating hospitals included all
major teaching hospitals throughout Australia and New
Zealand and participation required hospitals to commit to
registration of every off-licence use of rFVIIa at their
institution.
Patients in the ANZHR were identiﬁed by local investi-
gators through blood bank or pharmacy records of rFVIIa
administration. Trained data collectors extracted data from
medical records using a standardised case report form that
captured information related to: patient demographics (e.g.
age, gender); details of rFVIIa use (dose volume, body
temperature and blood pH); blood components transfused
before and after rFVIIa use (red blood cells (RBCs), fresh
frozen plasma (FFP), cryoprecipitate and platelets); use of
anticoagulant/antithrombotic medications prior to rFVIIa
use; clinician-assessed effect of rFVIIa on bleeding (stopped,
attenuated or unchanged e this was a subjective assess-
ment based on clinical judgement); thromboembolic (TE)adverse events, and mortality (24-h and 28-day). Patients
who either stopped or attenuated bleeding after rFVIIa
administration were categorised as responders whereas
patients with unchanged bleeding conditions were classiﬁed
as non-responders.
All data entries were veriﬁed and validated by registry
staff prior to inclusion on the registry. Data collected as part
of the ANZHR were subject to a rigorous quality control
and auditing process.24 Those patients receiving rFVIIa for
treatment of bleeding associated with AAA were identiﬁed
from text descriptions of the case. Data collectors at each
site were contacted to provide additional details (supple-
mentary data) on AAA cases to allow calculation of the
Hardman Index25 and the Physiological and Operative
Severity Score for the enUmeration of Mortality and
morbidity (POSSUM),26 which have been used previously
as mortality prediction tools in AAA patient populations.
Additional information was also requested including
aneurysm status (ruptured or non-ruptured), urgency of
surgery, type of surgery (open or EVAR) and location of
aneurysm.
The registry received ethics approvals from the Human
Research Ethics Committees of Monash University and all
participating hospitals to collect de-identiﬁed information
without patient consent.
Statistical analysis
All statistical analyses were performed using Stata version
11.2 (StataCorp, College Station, Texas, USA). We compared
characteristics and outcomes between ANZHR responders
and non-responders to rFVIIa. This analysis was performed
separately for patients presented with ruptured and non-
ruptured AAAs. Categorical variables were compared using
Fisher’s Exact Chi-Squared tests and continuous variables
using ManneWhitney (ranksum) tests. Logistic regression
analyses were carried out to identify predictors associated
with mortality. In addition, mortality risk in r-AAA patients
in the ANZHR was scored using the Hardman Index25 and
a POSSUM model speciﬁcally for r-AAA as described by
Prytherch et al.26 (R-POSSUM). The mortality risk in patients
with nr-AAA was scored according to the V-POSSUM model
as outlined by Tambyraja et al.27 Table 1 outlines the
variables and equations of POSSUM models plus the vari-
ables used for Hardman Index calculations. Each variable
included in the Hardman Index scores one point each and
patients were scored from 0 (lease severe) to 5 (most
severe). A P-value less than 0.05 was regarded as statisti-
cally signiﬁcant.RESULTS
Of the 3440 patients in the ANZHR, 106 (3%) had AAA as the
primary context of bleeding. Of these, additional (supple-
mentary) data were available for 77 (73%). Characteristics
of patients with and without supplementary information
showed no signiﬁcant difference in demographics, rFVIIa
dose size, bleeding response to rFVIIa or mortality (Table 2).
The analysis was therefore restricted to patients with
Table 2. Characteristics of Australian and New Zealand Haemostasis Registry AAA patients.
All ANZHR AAA patients
(Total ¼ 106)
Supplementary data available? P-value
No (n ¼ 29) Yes (n ¼ 77)
n (%) n (%) n (%)
Patient characteristics
Male gender 87 (82%) 22 (76%) 65 (84%) 0.2
Age (median [IQR] (range)) 73 [69, 78] (56, 89) 70 [64, 77] (58, 89) 73 [69, 79] (56, 88) 0.07
ICU admission 97 (92%) 26 (90%) 71 (92%) 0.7
Details of rFVIIa use
Place of rFVIIa administration (dose 1) 0.12
Operating theatre 67 (63%) 22 (76%) 45 (58%)
Intensive care unit 39 (37%) 7 (24%) 32 (42%)
Medication use prior to rFVIIa1
Aspirin 19 (22%) 5 (25%) 14 (21%) 0.8
Other anti-platelet medication 4 (5%) 1 (5%) 3 (5%) 1.0
Warfarin 10 (12%) 4 (20%) 6 (9%) 0.2
Heparin 12 (11%) 4 (14%) 8 (10%) 0.7
rFVIIa dose 1 (mg/kg) (median [IQR] (range)) 84 [64, 100] (12, 141) 94 [70, 106] (21, 113) 82 [60, 96] (12, 141) 0.2
Single dose only of rFVIIa 84 (79%) 21 (72%) 63 (82%) 0.3
Hypothermic (T < 35 C) at the time of rFVIIa
use2
24 (30%) 4 (19%) 20 (34%) 0.3
Acidotic (pH < 7.2) at the time of rFVIIa use3 44 (52%) 16 (67%) 28 (46%) 0.10
Outcomes
Bleeding Stopped/Reduced following rFVIIa
(responders)4
47 (49%) 12 (48%) 35 (50%) 1.0
Thromboembolic (TE) adverse events 14 (13%) 5 (18%) 9 (12%) 0.5
24-h mortality 30 (28%) 8 (28%) 22 (29%) 1.0
28-day mortality 65 (61%) 18 (62%) 47 (61%) 1.0
Data missing for 111; 219; 316; 47 patients.
Table 1. Variables and equations used for Hardman Index25 and Physiological and Operative Severity Score for the enUmeration of
Mortality and morbidity (POSSUM).26,27
Mortality predictive model Variables and equations
Hardman Index (r-AAA only) Age >76 years
ECG ischaemia
Creatinine >0.19 mmol/L
Loss of consciousness
Haemoglobin <9 g/L
POSSUM Physiological score Operative score
Age (years) Operative magnitude
Cardiac signs Number of procedures
Respiratory signs Blood loss (mL)
Systolic blood pressure (mmHg) Peritoneal contamination
Pulse (beats/min) Presence of malignancy
Glasgow coma score (GCS, 3e15) Mode of surgery
Urea nitrogen (mmol/L)
Sodium (mmol/L)
Potassium (mmol/L)
Haemoglobin (g/L)
White cell count (109/L)
Electrocardiogram
Equations
POSSUM ¼ ln

R
1 R

where R ¼ Risk of mortality
For ruptured AAA patients (R-POSSUM):
R ¼ 4.9795 þ (0.0913  Physiological score) þ (0.0958  Operative score)
For non-ruptured AAA patients (V-POSSUM):
R ¼ 8.0616 þ (0.1552  Physiological score) þ (0.1238  Operative score)
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hospitals across Australia and New Zealand (Fig. 1).
Approximately 84% (n ¼ 65) of the AAA patients were
male, and their median (IQR) age was 73 (69e79) years
(Table 2). Seventy-one patients (92%) were admitted to the
intensive care unit (ICU) following surgery: the 6 patients
who did not get admitted to the ICU were deceased within
24 h. Over 80% (n ¼ 63) of AAA patients received only
a single dose of rFVIIa and the median (IQR) rFVIIa dose was
82 (60e96)mg/kg. Approximately 46% (28/61) of patients
were severely acidotic (serum pH < 7.2) and 34% (20/58)
were hypothermic (core temperature <35 C) at the time of
rFVIIa use. Bleeding response to rFVIIa was known for 70
patients and 35 (50%) of them either stopped or attenuated
bleeding after rFVIIa administration (positive responders).
Nine patients had records of thromboembolic (TE) adverse
events (please see below for details) and by day 28
following rFVIIa use, 47 (61%) patients were deceased
(Table 2).
The majority of patients (n ¼ 56, 73%) had ruptured
aneurysms (r-AAA) at the time of hospital admission. About
75% (n ¼ 58) these surgeries were emergency procedures
with over 80% (n ¼ 57) having infra-renal aneurysms. Fifty-
three percent (10/19) of the non-ruptured (nr-AAA) and
49% (25/51) of r-AAA patients responded positively to
rFVIIa. Approximately 93% (n ¼ 71) of patients underwent
open surgical repair while the remaining 7% (n ¼ 5) had
endovascular repair (EVAR). All 5 patients with EVAR
(2 r-AAA and 3 nr-AAA) had returned to the ICU
following surgery. Two of these EVAR patients (1 r-AAA and
1 nr-AAA patient) responded positively to rFVIIa resulting in
stopped/attenuated bleeding. The 3 EVAR patients who did
not respond to rFVIIa died within 24 h after surgery. The
r-AAA patient with EVAR and demonstrated a positive
response to rFVIIa was also dead by day 28. Overall, 28-dayFigure 1. Distribution of AAA patients treated with off-label rFVIIa in
politan hospitals; 2rural hospital; 32rural and 9 metropolitan hospitals.mortality among these patients who underwent EVAR was
80% (4/5).
Table 3 reports the comparison of aneurysm details,
patient characteristics and outcomes between responders
and non-responders, stratiﬁed by aneurysm state. No
statistically signiﬁcant differences were found between
responders and non-responders in terms of patient aneu-
rysm details for either ruptured or non-ruptured AAA.
The single patient characteristic to demonstrate a statisti-
cally signiﬁcant difference between responders and non-
responders related to acidosis: signiﬁcantly more non-
responders in both nr-AAA and r-AAA patient groups were
acidotic (none vs. 71% (5/9) in nr-AAA group and 32%
(7/25) vs. 75% (15/26) in r-AAA group). In terms of patient
outcomes, approximately 24% (6/25) of responders in the
r-AAA group but none of the non-responders experienced
TE adverse events (P ¼ 0.01). The 24-h mortality was
signiﬁcantly higher in non-responders in both ruptured and
non-ruptured AAA patient groups (Table 3). Additionally,
the 28-day mortality in r-AAA non-responders was 92%
(24/26), which was signiﬁcantly higher than the responders
(40% (10/25), P < 0.01). The 28-day mortality rate in nr-AAA
non-responders was also higher than nr-AAA responders
(67% (6/9) vs. 30% (3/10)) although the difference was not
statistically signiﬁcant.
Furthermore, we examined the association between 28-
day mortality in ruptured AAA patients and a range of
factors including infra-renal aneurysm, gender, age, prior
medication use, acidosis, hypothermia, TE adverse events
and non-response to rFVIIa. In univariate analyses, only
non-response to rFVIIa was found to be signiﬁcantly asso-
ciated with 28-day mortality in r-AAA patients (OR ¼ 18
[95% CI: 3e94] P < 0.001). Logistic regression analyses
were not performed with nr-AAA group due to the small
number of patients.the Australian and New Zealand Haemostasis Registry. 1all metro-
Table 3. Comparison of characteristics between responders and non-responders to rFVIIa,a stratiﬁed by aneurysm status.
Non-ruptured Ruptured
Responders
(n ¼ 10)
Non-responders
(n ¼ 9)
P-value
Responders
(n ¼ 25)
Non-responders
(n ¼ 26)
P-value
Aneurysm details
Width1 mm
(median [IQR]
(range))
60 [47, 70](42, 280) 73 [49, 85](45, 100) 0.5 74 [65, 80] (9, 92) 69 [55.5, 79] (5, 860) 0.4
Length2 mm
(median [IQR]
(range))
52 [46, 120](40, 150) 71 [47, 78](45, 92) 0.7 84 [73, 93](18, 405) 80 [67, 110](8, 1350) 1.0
Infra-renal
aneurysm3 (%)
6 (67%) 7 (88%) 0.6 20 (83%) 18 (82%) 1.0
Operation type -
Open repair4 (%)
9 (90%) 7 (78%) 0.6 23 (96%) 25 (96%) 1.0
Duration of
operation h
(median [IQR]
(range))
6.0 [4.9, 6.2](3.0,10.2) 5.0 [4.1, 5.3](0.7, 8.3) 0.3 4.4 [2.9, 6.0](1.3, 18.0) 3.9 [3.2, 4.9](0.1, 20.0) 0.7
Characteristics
Male gender (%) 7 (70%) 8 (89%) 0.6 22 (88%) 23 (88%) 1.0
Age years (median
[IQR] (range))
78 [70, 82](64, 84) 81 [73, 82](68, 87) 0.6 73 [70, 78](60, 86) 73 [65,79](56, 88) 0.7
ICU admission (%) 10 (100%) 8 (89%) 0.5 25 (100%) 21 (81%) 0.05
Place of rFVIIa
administration
(dose 1) (%)
1.0 0.4
Operating
theatre
5 (50%) 4 (44%) 17 (68%) 14 (54%)
Intensive care
unit
5 (50%) 5 (56%) 8 (32%) 12 (46%)
Medication use prior to rFVIIa5 (%)
Aspirin 3 (30%) 3 (38%) 1.0 6 (29%) 2 (9%) 0.13
Other anti-platelet
medication
0 0 2 (10%) 0 0.2
Warfarin 1 (10%) 0 1.0 4 (19%) 1 (5%) 0.18
Heparin 4 (40%) 2 (22%) 0.6 1 (4%) 1 (4%) 1.0
rFVIIa dose
1 mg/kg (median
[IQR] (range))
99 [80, 103](60, 141) 87 [34, 93](29, 128) 0.19 80 [57, 86](12, 126) 80 [55, 90](12, 112) 0.720
Single dose only
of rFVIIa (%)
9 (90%) 6 (67%) 0.3 21 (84%) 22 (85%) 1.00
Hypothermic
(T < 35 C)
at the time of
rFVIIa use6 (%)
1 (10%) 3 (60%) 0.08 9 (43%) 7 (35%) 0.8
Acidotic
(pH < 7.2) at
the time of
rFVIIa use7 (%)
0 5 (71%) 0.01 7 (32%) 15 (75%) 0.01
Outcomes
Thromboembolic
(TE) adverse
events (%)
1 (10%) 1 (11%) 1.0 6 (24%) 0 0.01
24-h Mortality (%) 0 5 (56%) 0.01 0 16 (62%) <0.01
28-day Mortality
(%)
3 (30%) 6 (67%) 0.18 10 (40%) 24 (92%) <0.01
a Data on response to rFVIIa missing for 7 patients. Data missing for 117 (n ¼ 4 nr-AAA; n ¼ 13 AAA), 227 (n ¼ 3 nr-AAA; n ¼ 24 AAA),
37(n¼ 2 nr-AAA; n¼ 5 AAA), 41 (n¼ 1 AAA), 59 (n¼ 1 nr-AAA; n¼ 8 AAA), 614 (n¼ 4 nr-AAA; n ¼ 10 AAA), 712 (n¼ 3 nr-AAA; n¼ 9 AAA)
patients. P-values compare responders with non-responders. For differences in medians (continuous variables) P-values derived using
ManneWhitney (ranksum) tests and using Fisher’s exact Chi-Squared tests for categorical variables.
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A total of 11 TE adverse events were reported among 9 AAA
patients (12%) and the details are as presented in Table 4.
Six of the 9 patients with TE adverse events had ruptured
aneurysms. Interestingly, all these 6 r-AAA patients had
responded positively to rFVIIa either stopping or attenu-
ating bleeding. Of the 3 nr-AAA patients with TE adverse
events, one had responded positively to rFVIIa, one had not
responded to rFVIIa and response was recorded (unknown)
for one patient. Two of these patients with TE events were
on aspirin and another 2 were using Warfarin prior to
surgery. While all 9 patients survived the ﬁrst 24 h, 4
patients were deceased by day 28 (3 r-AAA patients and 1
nr-AAA patient with unknown bleeding response).POSSUM scores and Hardman Index in HR AAA patients
Mortality in ANZHR AAA patients was further compared to
predicted mortality, calculated using the Hardman Index
(Fig. 2) and POSSUM model: R-POSSUM for patients with
r-AAA and V-POSSUM for nr-AAA (Table 5). Although there
were differences between observed and expected deaths in
some categories, there was no statistically signiﬁcant
difference between overall observed and predicted
mortality with any model.
DISCUSSION
Our aim was to investigate the use of rFVIIa in patients
presenting with AAA and to describe their outcomes using
data from the Haemostasis Registry. To our knowledge, this
is the largest study of the off-label use of rFVIIa in this
patient group. In a univariate logistic regression analysis, we
observed a statistically signiﬁcant association between
positive bleeding response to rFVIIa and reduced mortality
in r-AAA patients. Mortality prediction models however did
not provide evidence to support this observation.
Surgery for AAA, especially in those with ruptured
aneurysms, carries a great risk of haemorrhage largely due
to coagulopathy, which is known to be a major cause of
intra-operative mortality.28 Various mechanisms are impli-
cated in coagulopathy: tissue injury can lead to platelet and
clotting factor consumption (consumption coagulopathy),
prolonged operation time, global hypoperfusion and intra-
operative replacement of large volumes of non-warmed
ﬂuids can contribute to both hypothermia and dilutional
coagulopathy.9 In addition, hypoperfusion due to cross-
clamping and subsequent reperfusion after unclamping isTable 4. Thromboembolic adverse events reported in ANZHR AAA
patients.
TE Adverse events n
Acute myocardial infarction (AMI) 3
Cerebrovascular accident (CVA) 2
AMI þ CVA 1
Deep vein thrombosis (DVT) 1
Arterial thrombosis (AT) 1
AT þ other thrombosis 1thought to induce ﬁbrinolysis and acidosis. In turn, both
hypothermia and acidosis can contribute to clotting factor
dysfunction, resulting in refractory coagulopathy.9 Modern
management of patients undergoing AAA repair with peri-
operative haemorrhage includes cell salvage mechanisms,
rapid administration of large amounts of red blood cells
(RBCs), platelets and plasma to prevent and treat coagul-
opathy.9,11 Additionally, procedures to minimise hypo-
thermia (e.g. use of warm ﬂuid infusion, forced air warming
and warm saline in surgical ﬁeld) and correction of acidosis
at an early stage, may be used to prevent coagulopathy.10
However, in those situations when bleeding is uncontrol-
lable and all conventional measures are ineffective, rFVIIa
has been used as an adjunctive therapy.
Approximately 50% of the Haemostasis Registry AAA
patients did not demonstrate any change in bleeding
condition after rFVIIa use, with the majority of these ‘non-
responders’ found to be acidotic at the time of rFVIIa use.
The precise impact of acidosis and hypothermia on rFVIIa
activity is an ongoing debate, with current evidence limited
to in vitro studies that report inconsistent results.29,30 In the
present study, a signiﬁcantly greater number of non-
responders were found to be acidotic (but not hypothermic)
at the time of rFVIIa administration, in both ruptured and
non-ruptured AAA cases. Yet, upon regression analysis, only
response to rFVIIa was found to be signiﬁcantly associated
with increased survival. This observation suggests that
response to rFVIIa may have inﬂuenced patient survival in
Haemostasis Registry AAA patients.
A limited number of studies investigating the use of
rFVIIa in AAA patients have reported improved survival in
those who demonstrate a reduction in or cessation of
bleeding. von Heymann et al. published a meta-analysis of
case series, and demonstrated that 73% of patients treated
with rFVIIa during abdominal, vascular and urological
surgery achieved at least a reduction of bleeding and that
the probability of survival was increased in these patients.31
Koncar et al. recently published one of the largest case
series (n ¼ 24) of vascular patients treated with rFVIIa.9
They compared the use of rFVIIa for intractable bleeding in
r-AAA and thoracoabdominal aortic aneurysm (t-AAA)
patients to a historical control group and found a signiﬁcant
reduction both in mortality and transfusion requirements.
While the patients with rFVIIa use (cases) were recruited
from July 2003 to January 2008, the control patients were
from January 1995 to July 2003, before rFVIIa was made
locally available.9 Advances in medical and surgical treat-
ment between 1995 and 2008 are likely to have biased
results in this study towards a reduced mortality in the
latter period that may confound any improvements due to
use of rFVIIa.
Since the patient population in this study was recruited
from several hospitals across Australia and New Zealand,
the treatment regimens in different hospitals would have
resulted in different management of patients causing
potentially different outcomes. This is a source of variation
and a limitation of this observational study. Additionally,
subjective assessment of bleeding response to rFVIIa might
Figure 2. Mortality in HR r-AAA patients compared to Hardman Index scores, stratiﬁed by bleeding response to rFVIIa.
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which is another limitation of this study. However, current
alternative methods for assessing bleeding response are
also similarly problematic. While coagulation parameters
such as PT and APTT may be used as indirect indicators of
response, these measures do not reﬂect real-time efﬁcacy
of rFVIIa in critical bleeding contexts. Also, while the
demand for blood components offers a potentially useful
tool for assessing response, reliable collection of these and
similar data is also difﬁcult. As part of quality control
procedures, the registry provided training in data abstrac-
tion to ensure standardised assessment of parameters
including bleeding response and undertook regular data
auditing procedures.24 Therefore, we believe that clinical
judgement was a reasonable tool for assessing bleeding
response in this context.Table 5. Mortality prediction according to published risk scores in HR
Risk score Mean predicted risk
of death (%)
No. of
patients
Predicte
deaths
R-POSSUM (r-AAA patients only)
40% 31.40 3 1
>40% to 60% 51.48 10 5
>60% to 70% 66.30 9 6
>70% to 80% 75.35 15 11
>80% to 100% 86.65 14 12
Total 68.93 51 35
V-POSSUM (nr-AAA patients only)
25% 12.6 5 1
>25% to 50% 36.96 7 3
>50% to 75% 63.35 3 2
>75% to 100% 92.17 4 4
Total 46.34 19 9
Hardman Index (r-AAA patients only)
0 16 8 1
1 37 13 5
2 72 20 14
>2 100 10 10
Total 59.78 51 30To date, there have been no clinical trials investigating
the use of rFVIIa for the treatment of bleeding in patients
with AAA. Without an appropriate comparator or control
group, and with the mortality prediction tools showing no
overall beneﬁt in mortality rate, it is difﬁcult to rule out the
possibility that Haemostasis Registry patients who survived,
would have survived regardless. Furthermore, not all vari-
ables that may impact outcomes in patients with AAA (such
as if the AAA was symptomatic or mycotic etc.) were
included in the original data collection for the ANZHR.
Although this study is one of the largest of its type, the
sample size in the analysis remains small. Nonetheless, the
strong association between non-response to rFVIIa and
mortality observed in the Haemostasis Registry AAA
patients is difﬁcult to over-look. Therefore, further studies
are needed to more thoroughly explore the precise role ofAAA patients.
d Observed
deaths
rFVIIa
responders (%)
Observed deaths in
rFVIIa responders (%)
1 2 (67%) 0 (0%)
8 5 (50%) 3 (60%)
5 4 (44%) 0 (0%)
10 8 (53%) 4 (50%)
11 6 (43%) 4 (67%)
35 25 (49%) 11 (44%)
4 2 (40%) 1 (50%)
5 3 (43%) 2 (67%)
0 2 (67%) 0 (0%)
0 3 (75%) 0 (0%)
9 10 (53%) 3 (30%)
3 7 (88%) 2 (29%)
10 5 (38%) 2 (40%)
15 8 (40%) 5 (63%)
6 5 (50%) 1 (20%)
34 25 (49%) 10 (40%)
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meantime, clinicians are likely to continue using rFVIIa in
cases when conventional therapeutic options have failed
and the patient is at risk of exsanguination.
In other studies of ruptured AAA patients, the mortality
rates assessed against POSSUM risk categories are highly
variable, although patient numbers per study are typically
small. Bown et al. reported only 57% (4/7) mortality in
patients with mortality risk above 75%,5 while Sandford et al.
reported 75% mortality (3/4) in patients with greater than
80% mortality risk.32 Another larger series by Harris et al.
reported 84% mortality in patients with mortality risk above
80%,33 while for the same risk group Neary et al. reported
89% mortality.34 In our study, observed mortality in r-AAA
patients receiving rFVIIa who had a mortality risk >80%, was
79% (11/14). Therefore, since overall predicted and observed
mortalities were similar despite several differences at
different risk strata, evidence from this analysis does not
allow us to conclude that use of rFVIIa made a statistically
signiﬁcant contribution to improved survival.CONCLUSION
Observations in this study suggest that Haemostasis
Registry AAA patients were gravely ill and those who
responded positively to rFVIIa had an improved survival
rate. Despite this, predictive models of mortality did not
show improved survival following rFVIIa administration.
Carefully planned, randomised clinical trials in this patient
population are therefore required to help identify if and
when rFVIIa should be used in this patient group at high risk
of exsanguination.ACKNOWLEDGEMENTS
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